Newsbenzinga
Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal
· Published
Article summary
Foghorn Therapeutics stock drops as Eli Lilly ends partnership, prompting a 40% workforce cut to extend cash runway into 2029 while pivoting pipeline.
An excerpt from the original article.
Comments —
Loading comments…